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Abstract
Background: In patients with type-2 diabetes receiving oral antidiabetic drugs (OADs), the addition of insulin is
frequently required to achieve sufficient control over blood glucose levels. It is, however, difficult to predict if, when
and in which patients insulin therapy will be needed. We aimed to identify patient related variables associated with
the addition of basal insulin to oral therapy resulting in a basal supported oral therapy (BOT).
Methods: DIVE (DIabetes Versorgungs-Evaluation) is a prospective, observational, multi-centre diabetes registry
established in Germany in 2011. For the present explorative analysis, 31,008 patients with type-2 diabetes prescribed
at least one OAD were included. Patients who had previously received insulin and those over 90 years old were
excluded. The event of interest was defined as the initiation of BOT during the observational period. Cause-specific
Cox proportional hazards models based on a competing risk framework were applied for risk quantification.
Results: Multivariable adjusted hazard ratios demonstrated that longer diabetes duration, higher BMI, poorer
glycaemic control, documentation of any micro- or macrovascular comorbidity, the presence of concomitant
non-antidiabetic pharmacotherapies, and greater numbers of prescribed OADs increased the likelihood of BOT
initiation. On the other hand BOT initiation was less likely in patients with older age and female gender. Analysing
the likelihood of OAD termination without initiation of BOT provided supportive evidence for the variables
predictive of BOT initiation.
Discussion: Analysis of the DIVE registry has resulted in the identification of a number of factors that may be
predictive for the initiation of BOT for type-2 diabetes patients initially prescribed one or more OADs. Poor
glycaemic control, the presence of vascular comorbidities and concomitant medications, and a greater number of
OADs were all detected to increase the risk of a switch to BOT. Female gender and younger age showed protective
properties.
Conclusions: The close monitoring of patients displaying these characteristics may help to identify individuals who
might benefit from early addition of insulin therapy to their oral treatment regimen.
Keywords: Oral antidiabetic drug, Insulin, Basal, Glycaemic control, Long-acting, Competing risks, Cox proportional
hazards model
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Background
The first line treatment for patients with type-2 diabetes
that cannot be controlled by diet alone is generally
monotherapy with an oral antidiabetic drug (OAD) such
as metformin. However, such treatment is rarely effective
over an extended period of time [1]. Progressive decline
in β-cell function along with decreasing insulin sensitiv-
ity generally necessitate the addition of other OADs, and
eventually, insulin therapy is required in order to achieve
adequate glucose control [2, 3].
Guidelines suggest that insulin therapy should be initi-
ated when glycated haemoglobin (HbA1c) levels cannot
be reduced below 7.5 % (58 mmol/mol) using OADs
alone [4, 5]. A number of studies have demonstrated sig-
nificant reductions in blood glucose levels with the
addition of insulin to oral therapy [6, 7]. Moreover, the
presence of OADs reduces the required dosage of insulin
in comparison to when it is used alone [8]. There are
three main options for the administration of insulin:
conventional therapy (pre-mixed insulin), short-acting
(prandial or supplementary), and long-acting (basal)
therapy. While conventional therapy and short-acting in-
sulin have been shown to achieve lower HbA1c levels,
they are associated with weight gain and a higher risk of
hypoglycaemia in comparison to the provision of a long-
acting form [9]. The addition of basal insulin to an OAD
regimen is termed basal supported oral therapy (BOT).
The requirement for only a single injection per day is a
great advantage of this treatment option, which is sig-
nificant considering the reluctance of patients and clini-
cians alike to initiate insulin therapy [10–12].
There has been limited assessment of the characteris-
tics of patients that convert to BOT. One study per-
formed by Kostev et al. demonstrated that younger
patients (<50 years) were more likely to switch to this
treatment regimen [13]. They also found that BOT initi-
ation was associated with shorter diabetes duration. The
aim of the present analysis was to more clearly elucidate
which factors could serve as predictors for the necessity
to start BOT.
Methods
Study design
DIVE (DIabetes Versorgungs-Evaluation) is a prospective,
observational, multi-centre diabetes registry established in
Germany in 2011 [14]. Enrolment of patients started dur-
ing the year 2011 with a retrospective capture of data back
to January 1st 2011. All patients enrolled for the registry
provided written informed consent. Since then patients
have been prospectively followed and the registry is still
ongoing. For the purpose of data collection, the diabetes
specific documentation software ‘DPV2 Diamax’ (Axaris
Software and Systems GmbH, Germany) was used. The
protocol received ethical approval from the Hannover
Medical School Ethics Committee.
For the current, explorative analysis, we considered only
patients with type-2 diabetes and locked the data October
31st 2014. Time origin was set to OAD initiation with at
least one OAD (Fig. 1) that might have occurred even be-
fore start of DIVE registry was allocated to the first re-
corded OAD therapy since the start of DIVE-database.
Patients already receiving any insulin therapy and patients
older than 90 years were excluded (Figs. 1 and 2).
Definitions of OADs and BOT used in the present study
The ATC index 2014 of the WHO Collaborating Centre
for Drug Statistics and Statistics Methodology was used
for classification of any drugs involved in the study
(Additional file 1). OADs were defined as substances
with an ATC index of A10B, excluding injectables such
Fig. 1 Competing risks model resulting from the observable data and including study-specific criteria. Time origin was set to OAD initiation. Any
record of insulin use prior to baseline led to exclusion. Study entry (baseline) took place when firstly OAD prescription was recorded (state 0).
State 1 represents BOT initiation, state 2 represents stopping OAD medication without BOT initiation being observed. Individuals with neither of
these two events within the observational period were right-censored
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as human insulin and glucagon-like peptide-1 (GLP-1)
agonists (A10BX04, A10BX07, and A10BX10). BOT was
defined as the administration of one or more OADs in
combination with the injection of long-acting insulin(s)
(A10AE) and/or intermediate-acting neutral protamine
Hagedorn (NPH)-insulin (A10AC01). Concomitant not
diabetes related drugs were identified by ATC indices
other than A10. Records of equal medications less than
6 months apart (e.g. metformin at baseline, missing
documentation at one visit, metformin documentation
at the next visit) were merged into one episode. Patients
without further information regarding changes to their
treatment were treated as dropouts 6 months after the
last available medication record.
Documentation
Exact dates of birth and of the diabetes diagnosis were
not available. For this reason instead, time points were
set as June 30th of the corresponding year, or the 15th of
the corresponding month in order to enable the calcula-
tion of diabetes duration and patient age. Master data
provided information about gender and diabetes type.
Other patient characteristics at study entry including
height, weight, number of OADs and concomitant
medications, comorbidities, and laboratory values for
fasting plasma glucose (FPG), postprandial plasma glucose
(PPG), and HbA1c were derived from that doctoral visit,
which was no more than 90 days prior to and 30 days after
individual’s study entry. Individuals with no recorded visit
within this time period were excluded from the study
population (n = 14,772; Fig. 2). Relative HbA1c (%) was ex-
tracted from the available absolute HbA1c (mmol/mol)
according to the following equation [15]:
HbA1cð%Þ ¼ HbA1c
mmol
mol
 
10:929
þ 2:15:
The comorbidity profile of each patient was subdivided
into (patient or physician reported) microvascular and
macrovascular diseases within the year prior to study
entry. The former included any record of retinopathy,
blindness, nephropathy, renal failure, dialysis, or neur-
opathy. The latter includes transient ischaemic attack
(TIA)/prolonged reversible ischaemic neurologic deficit
(PRIND), stroke, coronary heart disease, myocardial in-
farction, and peripheral arterial disease. Similarly, (patient
or physician reported) hypoglycaemia was defined as in-
formation about any severe hypoglycaemic event. Diabetes
duration was computed as the time difference between
diabetes diagnosis and study entry. At this stage, all vari-
ables were checked for plausibility.
Statistics
To deal with missing data concerning diabetes duration,
height, weight, FPG, and PPG (Additional file 2), the
semi-parametric multiple imputation procedure of van
Buuren, which is based on a chained equation approach,
was applied [16] using the R-package mi [17]. Following
Fig. 2 Patient flow chart. The final study population contained 31,008 individuals. Out of them, 6705 to BOT were observed. 24,303 patients did
not initiate BOT within the observational period
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the ‘missing at random’ (MAR) assumption, conditional
regression models were built on all relevant baseline vari-
ables in addition to the individual outcomes. The imputed
values for weight and height were used to calculate BMI.
Analyses were conducted across ten imputed datasets.
Pooled estimates were computed using Rubin’s Rule [18]
and the R-package mitools [19]. Missing information
about (severe) incidences like patient or physician re-
ported hypoglycaemia and comorbidity profiles were as-
sumed to be sufficiently reliable, i.e., treated as ‘not
occurred’. Therefore, their imputation was not performed.
PPG was also not imputed, since it was missing in 75 % of
all individuals (Additional file 2: Table S2).
For descriptive purposes, mean differences (MDs) in
continuous baseline covariates comparing the groups of
patients with and without subsequent initiation of BOT
(in the following named BOT(observed) and BOT(not
observed)) were derived. Welch’s t-tests provided 95 %
confidence intervals (CIs). Fisher’s exact test was used
for categorical data. P-values of the corresponding odds
ratios (OR) were presented. All descriptive statistics were
based on available cases; i.e., they condition on observed
future BOT outcomes.
Risks were expressed in terms of unadjusted and mul-
tivariable adjusted hazard ratios (HRs) with 95 % CIs ob-
tained from Cox proportional hazards models regarding
the event of interest ‘Initiation of BOT’ (state 1). All in-
dividuals initiating OAD therapy before study entry were
handled as left-truncated data, i.e., they entered the risk
sets associated with the Cox model at their individual
times since start of OAD upon study entry. The event of
interest was subject to competing risks, because BOT
initiation may be precluded by stopping OAD therapy or
by switching to insulin alone. We therefore additionally
fitted a Cox model to the competing endpoint (state 2),
‘End of OAD therapy (without prior BOT initiation)’. In
addition to dropouts, patients neither observed to initi-
ate BOT nor stop OAD therapy up to October 31st,
2014 were treated as right-censored observations.
Figure 1 gives a multistate description of the model
that was used.
For the present analysis, it was not possible to also
model the occurrence of ‘death (while on OAD and with-
out initiation of BOT)’ due to sparse mortality information
within the DIVE registry (only 71 deaths were recorded,
cf. Fig. 2). All results were essentially comparable to a
sensitivity analysis including only patients with complete
covariate information (Additional file 3: Table S3). Data
input, processing, management, and analyses were con-
ducted by using R, Version 3.1.1.
Results
Patient characteristics at study entry
Out of the more than 130,000 patients with diabetes regis-
tered within the DIVE database, 31,008 met the inclusion
criteria for the present analysis (Fig. 2). Of these, 6705 in-
dividuals (21.6 %) were observed to initiate BOT. Patient
characteristics at study entry are given in Tables 1 and 2.
In terms of laboratory values, the average HbA1c level
was 7.5 % (SD: 1.2), with average FPG and PPG levels be-
ing 8.1 mmol/l (SD: 1.5) and 9.5 mmol/l (SD: 4.7). Note
that the latter two parameters were available for only 21.4
and 14.2 % of patients (Additional file 2: Table S2).
Impact of demographics on treatment regimen
Adjusted hazard ratios suggested that a higher BMI (HR:
1.012; 95 % CI: 1.007 to 1.017; Table 3) and longer dia-
betes duration (HR: 1.046; 95 % CI: 1.043 to 1.049) sig-
nificantly increased the risk of BOT initiation, although
the HRs are close to one. In contrast, female gender re-
duced the risk by about 5 % (HR: 0.950; 95 % CI: 0.903
to 0.998). These results are in accordance with the
purely descriptive analyses (Tables 1 and 2). However,
while a non-significant mean difference in age of −0.05 years
(95 % CI: −0.36 to 0.25; Table 1) was found between the
groups, the more precise Cox regression indicated that
Table 1 Characteristics of patients with or without observed initiation of BOT (continuous variables)
Covariate Total population BOT(observed) BOT(not observed) MD (95 % CI)
(N = 31,008) (N = 6,705) (N = 24,303)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 62.4 (3.5) 62.4 (3.4) 62.5 (3.5) −0.05 (−0.36, 0.26)
BMI (kg/m2) 32.4 (2.6) 33.0 (2.5) 32.2 (2.6) 0.7 (0.52, 0.93)
Weight (kg) 93.2 (4.6) 95.2 (4.6) 92.6 (4.6) 2.6 (1.9, 3.23)
Diabetes duration (years) 8.2 (2.7) 10.6 (2.8) 7.5 (2.7) 3.1 (2.86, 3.31)
HbA1c (%) 7.5 (1.2) 8.0 (1.2) 7.4 (1.2) 0.6 (0.55, 0.65)
FPG (mmol/l) 8.1 (1.5) 8.7 (1.6) 8.0 (1.5) 0.7 (0.58, 0.78)
PPG (mmol/l)a 9.5 (4.7) 10.8 (4.3) 9.1 (4.7) 0.9 (0.70, 1.14)
Legend: BOT basal supported oral therapy, MD mean difference, BMI body mass index, HbA1c glycated haemoglobin, FPG fasting plasma glucose, PPG postprandial
plasma glucose. Confidence intervals (CIs) for the mean difference were derived by Welch’s t-tests
abased on the available data: N = 7,382 (Total), 1,635 (BOT(observed)), 5,747 (BOT(not observed))
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age did in fact have an effect. The multivariable adjusted
HR of 0.993 (0.991 to 0.996; Table 3) showed a risk reduc-
tion for older individuals. This effect was reinforced by
the HR for ending OAD therapy, where an increased risk
was associated with an older age (HR: 1.003, 95 % CI:
1.001 to 1.005).
Impact of glycaemic control on treatment regimen
Table 3 shows that higher HbA1c levels were strongly
associated with the initiation of BOT (HR: 1.227; 95 %
CI: 1.197 to 1.257). This is in accordance with the ob-
served HbA1c mean value of 8.0 % (SD: 1.2; Table 1)
found for the BOT(observed) group, which was approxi-
mately 0.6 % higher than that of the group with no ob-
served BOT initiation (95 % CI: 0.55 to 0.65). The
unadjusted Cox analysis (Table 3) and the unadjusted
descriptive analysis showed that FPG was significantly
linked to the likelihood of BOT initiation. However, no
association was detected in the multivariate analysis
(HR: 1.022; 95 % CI: 0.999 to 1.046; Table 3). FPG was
consistently found to have no impact on the likelihood
of the competing endpoint of ending OAD therapy with
no BOT initiation. Descriptive analysis found slightly
higher PPG levels in patients with observed BOT initi-
ation (MD: 0.9 mmol/l; 95 % CI: 0.7 to 1.14); however,
the calculation was based on a restricted sample of
patients.
Impact of hypoglycaemia, micro-, and macrovascular
diseases on treatment regimen
Only 86 individuals (0.2 %, Table 2), who had suffered
episodes of hypoglycaemia during the 12 months prior
to their study entries, were noted. Of these, 36 switched
to BOT during the observational period. Despite this
small proportion of patients, a strong association be-
tween patient reported hypoglycaemic incidences and
BOT initiation was detected (HR: 1.708, 95 % CI: 1.208
to 2.416; Table 4). Further, patient or physician reported
micro- (HR: 1.141; 95 % CI: 1.082 to 1.203) and/or
macrovascular diseases (1.065; 95 % CI: 1.004 to 1.130)
were associated with an increased risk of BOT initiation.
These results are consistent with the purely descriptive
results given in Table 2.
Impact of OAD therapy on treatment regimen
A total of 86.6 % of patients were receiving a single
OAD at study entry, the most common being metformin
(64.1 %), sulfonylureas (14.6 %), or dipeptidyl peptidase-
4 (DPP-4) inhibitors (13.4 %; Table 4). In contrast to all
other compounds, Welch’s t-tests only detected sig-
nificant associations for glinides and DPP-4 inhibitors
(p < 0.001 and p < 0.0001, respectively). As can be seen
in Table 4, more than one prescribed OAD at study
entry corresponded to an increased risk for BOT initi-
ation compared to oral monotherapy. Specifically, two
OADs at study entry increased the likelihood of BOT
being initiated (HR: 1.121; 95 % CI: 1.047 to 1.199,
Table 3). An impact of three OADs at study entry was
only detectable if the corresponding strong risk reduc-
tion regarding the competing endpoint was taken into
account (HR: 0.604; 95 % CI: 0.482 to 0.758). Around
45 % of participants received concomitant medications
(Table 4). These individuals were subject to a greater risk
for BOT initiation (HR: 1.094, 95 % CI: 1.042 to 1.149;
Table 3). Note that the direct effects corresponding to
two OADs and concomitant medications were further
Table 2 Characteristics of patients with or without observed initiation of BOT (categorical variables)
Covariate Total population BOT(observed) BOT(not observed) p-value
(N = 31,008) (N = 6,705) (N = 24,303)
n (%) n (%) n (%)
Gender
Male 16,728 (53.9) 3,698 (55.2) 13,030 (53.6) 0.026
Female 14,280 (46.1) 3,007 (44.8) 11,273 (46.4)
Microvascular diseasesa
Yes 10,851 (35.0) 2,643 (39.4) 8,208 (33.8) <0.0001
No 20,157 (65.0) 4,062 (60.6) 16,095 (66.2)
Macrovascular diseases
Yes 7,377 (23.8) 1,711 (25.5) 5,666 (23.3) <0.001
No 23,631 (76.2) 4,994 (74.5) 18,637 (76.7)
Hypoglycaemia
Yes 86 (0.3) 36 (0.5) 50 (0.2) <0.0001
No 30,922 (99.7) 6,669 (99.5) 24,253 (99.8)
Legend: BOT basal supported oral therapy. Test for independence between groups by means of Fisher’s exact tests
aPatient and/or physician reported data
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(indirectly) increased because the risk of the competing
endpoint was decreased.
Discussion
Out of the 31,008 patients, who fulfilled the inclusion
criteria in the registry, more than 20 % initiated BOT
during the observational period. This value was higher
than that reported by Kostev et al. (12.8 %), who also in-
vestigated initiation of BOT in patients being treated
with OADs [13]. In accordance with that investigation,
the present Cox analysis also found that younger age
was associated with addition of basal insulin treatment.
One potential reason for this is that younger age at diag-
nosis can indicate more severe disease, which may
favour treatment with the combination of OADs and in-
sulin. Kostev et al. [13] also found a risk increase in
women; however, the present study showed the opposite
effect. Higher BMI was also found to be associated with
the initiation of BOT. This factor has been previously
shown to be predictive for a need for multiple antidia-
betic therapies for achieving target blood glucose levels
[1]. Furthermore, the lower dosage of insulin generally
required when used in conjunction with OADs in com-
parison to when used alone may limit weight gain, which
would be especially beneficial in overweight patients [9].
In the present investigation, the risk for BOT initiation
was found to be increased for patients with longer dia-
betes durations at study entry. In addition to the pro-
gressive loss of β-cell function that would have occurred
over time, these patients are likely to have experienced
more extensive periods of inadequate HbA1c levels,
resulting in a need to intensify treatment with the
addition of insulin to the oral therapy. Moreover, pro-
longed attempts to identify an effective oral treatment
regimen may have failed, while a clinician could perceive
benefits to continuing with such a strategy in patients
with a more recent diagnosis.
The mean HbA1c level at study entry was found to be
higher for the group of patients that switched to BOT.
The observed mean value of 8.0 % is close to levels that
have been stated to correspond to the point at which
oral therapy has failed and insulin initiation is advised
(≥8 % [20], ≥7.5 % [4, 5]). Patients not observed to initi-
ate BOT had an average HbA1c level closer to the <7 %
generally considered to be the target value for patients
with type-2 diabetes [3]. In accordance with this result,
descriptive analyses demonstrated higher FPG and PPG
levels in the BOT(observed) group. Multivariable ad-
justed HRs supported HbA1c as a strong predictor for
BOT. These data indicated that patients with poorer gly-
caemic control were more likely to switch to BOT dur-
ing the observational period, which is in agreement with
a previous study [13].
The presence of micro- and macrovascular diseases
was found to be highly indicative of BOT initiation. It is
possible that the occurrence of such events in patients
being treated with OADs would encourage a physician
to alter the antidiabetic therapy in order to improve gly-
caemic control.
The patients enrolled in the registry were prescribed a
wide range of OADs either as monotherapy or in differ-
ent combinations, at the discretion of the treating phys-
ician. Interestingly, descriptive analysis indicated that the
use of glinides or DPP-4 inhibitors was associated with a
higher risk of BOT initiation. This may merely be a fur-
ther indication of the greater risk of BOT associated with
Table 3 Predictors of switch to BOT: Univariate and multivariate
(pooled) HRs and corresponding lower and upper bounds of
the 95 % CIs
Endpoint
BOT OAD-End
(N = 6,705) (N = 10,547)
Univariate
Age 1.000 (0.998,1.002) 1.002 (1.001,1.004)
BMI 1.016 (1.012,1.020) 1.006 (1.004,1.010)
Diabetes duration 1.044 (1.041,1.047) 1.003 (0.999,1.007)
HbA1c 1.264 (1.245,1.284) 1.003 (0.984,1.022)
FPG 1.127 (1.109,1.046) 1.011 (0.999,1.023)
Gender 0.934 (0.891,0.981) 1.001 (0.963,1.040)
Microvascular diseasesa 1.226 (1.168,1.287) 0.974 (0.936,1.014)
Macrovascular diseasesa 1.115 (1.056,1.178) 1.131 (1.083,1.182)
Hypoglycaemiaa 2.567 (1.850,3.563) 1.007 (0.634,1.599)
No. OADs at baseline 2 vs. 1 1.288 (1.206,1.376) 0.679 (0.636,0.725)
No. OADs at baseline 3 vs. 1 1.295 (1.054,1.592) 0.605 (0.483,0.758)
Concomitant Medication
yes vs. no
1.144 (1.090,1.200) 0.834 (0.802,0.866)
Multivariate
Age 0.993 (0.991,0.996) 1.003 (1.001,1.005)
BMI 1.012 (1.007,1.017) 1.009 (1.005,1.012)
Diabetes duration 1.046 (1.043,1.049) 1.003 (0.999,1.007)
HbA1c 1.227 (1.197,1.257) 0.999 (0.970,1.029)
FPG 1.022 (0.999,1.046) 1.014 (0.997,1.033)
Gender 0.950 (0.903,0.998) 0.995 (0.956,1.035)
Microvascular diseasesa 1.141 (1.082,1.203) 0.947 (0.908,0.988)
Macrovascular diseasesa 1.065 (1.004,1.130) 1.152 (1.100,1.208)
Hypoglycaemiaa 1.708 (1.208,2.415) 0.956 (0.601,1.520)
No. OADs at baseline 2 vs. 1 1.121 (1.047,1.199) 0.680 (0.636,0.727)
No. OADs at baseline 3 vs. 1 0.981 (0.796,1.210) 0.604 (0.482,0.758)
Concomitant Medication
yes vs. no
1.094 (1.042,1.149) 0.824 (0.793,0.857)
Legend: BOT basal supported oral therapy, BMI body mass index, HbA1c glycated
haemoglobin, FPG fasting plasma glucose, OAD oral antidiabetic drug, HR hazard
ratio. Multivariate adjustment includes all factors given in the table
aPatient and/or physician reported
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poorer glycaemic control. We found that metformin use
was not associated with a higher likelihood of BOT initi-
ation, which might be indicative of physicians preferring
to try an alternative oral regime before incorporating in-
sulin. We also found that sulfonylurea use had no im-
pact on risk of BOT initiation. The combination of
metformin and a sulfonylurea is a well-established sec-
ond line treatment; however, if this does not achieve ad-
equate glycaemic control, the most suitable option for
therapy intensification is unclear. Whilst guidelines
suggest insulin should be initiated if an HbA1c level
of ≤7.5 % (58 mmol/mol) cannot be maintained by using
oral medication alone [21], there is often significant hesi-
tation on the part of the physician to introduce such ther-
apy [4, 5, 10, 12]. It is therefore possible that for patients
receiving a sulfonylurea, there is a comparable chance of
BOT initiation and change in oral therapy.
On the other hand, the more recently introduced gli-
nides and DPP-4 inhibitors are less likely to be used as
monotherapies, and at the time that the DIVE registry
was established were generally only used after failure of
metformin and/or sulfonylureas [2, 21]. Inadequate gly-
caemic control by OAD treatments including multiple
agents would indicate a necessity for insulin administra-
tion, often in the form of BOT [8]. Furthermore, both gli-
nides and DPP-4 inhibitors are compatible with insulin
therapy, and the combinations have been shown to be
highly effective for achieving glycaemic control [22, 23].
The prescription of more than one OAD was also indi-
cative of conversion to BOT, in agreement with the
study by Kostev et al. [13]. It is likely that treatment in-
tensification for patients receiving a single OAD at base-
line would proceed via prescription of a second oral
drug rather than insulin. This is in agreement with our
data showing that metformin use was not indicative of
BOT initiation. As this agent is usually the first line
pharmacological therapy for patients with type-2 dia-
betes, the majority of those receiving a single OAD at
baseline would be taking metformin.
The presence of concomitant medications was also
found to be a negatively associated with the initiation of
BOT. This is in accordance with the identified incidence
of micro- and macrovascular disease in patients that
switched to BOT, as comorbidities generally correlate
with number of drugs being administered.
Some limitations affected the certainty of the present
findings. 1) The determination of OAD and BOT pe-
riods was based on preliminary assumptions. Periods
that were less than 6 months apart were merged into
one period. Furthermore, missing information about the
end of treatments were right-censored 6 months after
the last available medication record because prescrip-
tions are usually made for a period of 3 months, and
rarely beyond 6 months. However, these choices were
clinically defensible as there may have been cases where
antidiabetic treatment was prescribed by other physicians,
Table 4 Antidiabetic and concomitant pharmacotherapy with or without observed initiation of BOT
Treatment Total Population BOT(observed) BOT(not observed) p-value
(N = 31,008) (N = 6,705) (N = 24,303)
n (%) n (%) n (%)
Monotherapy
Metformin 19,866 (64.1) 4,235 (63.2) 15,651 (64.4) 0.06
Sulfonylurea 4,532 (14.6) 1,012 (15.1) 3,520 (14.5) 0.21
Glucosidase inhibitors 241 (0.8) 56 (0.8) 185 (0.8) 0.53
Glitazones 158 (0.5) 33 (0.5) 125 (0.5) 0.92
Glinides 1397 (4.5) 361 (5.4) 1,036 (4.3) <0.001
DPP-4 inhibitor 4,141 (13.4) 1,023 (15.3) 3,118 (12.8) <0.0001
No. of OADs <0.0001
1 OAD 26,861 (86.6) 5,564 (83.0) 21,297 (87.6)
2 OADs 3,818 (12.3) 1,049 (15.6) 2,769 (11.4)
≥ 3 OADs 329 (1.1) 92 (1.4) 237 (1.0)
Concomitant medication <0.0001
no drug 16,959 (54.7) 3,409 (50.8) 13,550 (55.8)
1 drug 5,762 (18.6) 1,150 (17.2) 4,612 (19.0)
2 drugs 2,697 (8.7) 566 (8.4) 2,131 (8.8)
≥ 3 drugs 5,590 (18.0) 1,580 (23.6) 4,010 (16.5)
Legend: BOT basal supported oral therapy, DPP dipeptidyl peptidase, OAD oral antidiabetic drug. Test for independence between groups by means of Fisher’s
exact test
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and therefore not recorded. 2) Medication prescriptions
before the start of DIVE were generally unknown or as-
sumed to be inaccurate. For persons with recent diabetes
diagnosis dates, the OAD initiation was based on up-
to-date registry data. In contrast, the OAD initiation
for persons being not recently diagnosed was only de-
terminable by means of the recorded prescription data.
3) The present investigation did not impute missing
PPG levels as these were absent for such a high propor-
tion of patients (75 %); therefore, information was ex-
pected to be too speculative. For this reason, analysis
of PPG was performed using only descriptive mea-
sures, with further investigation required to determine
any potential impact of this variable. 4) Hypoglycaemic
events and clinical diagnoses regarding comorbidities
were recorded based on recollection by the patient rather
than medical records; therefore, some inaccuracies may
have been introduced into the analysis. Nevertheless, the
information was assumed to be sufficiently reliable as
events were likely to have been severe in nature. 5) All
analyses were conducted by means of censoring possible
competing death events as the DIVE registry contained a
very small number of deaths. Nevertheless, the present ap-
proach produced valid HR estimates (Competing risks
and multistate models with R), but probability predictions
and individual prediction models would require additional
mortality information.
The major strength of the present investigation was
the high number of patients and the quality of the data.
The register-based dataset provided a high number of
eligible individuals and a reasonable number of events.
This allowed the computation of point estimates with
very small confidence intervals. Missing information for
covariates led not to exclusion, but was addressed by
means of a multiple imputation approach. The compet-
ing risks model allowed for left-truncated data, where in-
dividuals entered the risk set at different time points.
However, the analysis required the use of covariate infor-
mation collected at study entry and, thus, not necessarily
at OAD initiation. The temporal development of the
medical problem was adequately taken into account and
it was not conditional on future events. Simultaneous
analysis of the competing endpoint also led to a better
understanding of the underlying processes [24], and en-
abled the detection of indirect covariate effects on the
risk of BOT initiation.
Conclusions
Analysis of the DIVE registry has resulted in the identifi-
cation of a number of factors that may be predictive for
the initiation of BOT for type-2 diabetes patients initially
prescribed one or more OADs. Poor glycaemic control,
the presence of vascular comorbidities and concomitant
medications, and a greater number of OADs were all
detected to increase the risk of a switch to BOT. Female
gender and younger age showed protective properties.
The close monitoring of patients displaying these char-
acteristics may help to identify those for whom oral ther-
apy alone is unlikely to be sufficient, and therefore who
might benefit from early addition of insulin therapy to
their treatment regimen.
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